- Broschiertes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
This book explores the controversial relationship between physicians and the pharmaceutical industry, identifies the ethical tensions and controversies, and proposes numerous reforms both for medicine's own professional integrity and for effective public regulation of the industry.
Andere Kunden interessierten sich auch für
Tara FlanaganNarrative Medicine in Hospice Care39,99 €
Helen B. HolmesBirth Control and Controlling Birth77,99 €
Helen B. HolmesBirth Control and Controlling Birth103,99 €
H. A. ShenkinMedical Ethics61,99 €
Reprogenetics56,99 €
Corrado Viafora (ed.)Clinical Bioethics129,99 €
Frida Simonstein (ed.)Reprogen-Ethics and the Future of Gender159,99 €-
-
-
This book explores the controversial relationship between physicians and the pharmaceutical industry, identifies the ethical tensions and controversies, and proposes numerous reforms both for medicine's own professional integrity and for effective public regulation of the industry.
Produktdetails
- Produktdetails
- Verlag: Rowman & Littlefield Publishers
- Seitenzahl: 382
- Erscheinungstermin: 9. November 2007
- Englisch
- Abmessung: 229mm x 152mm x 22mm
- Gewicht: 619g
- ISBN-13: 9780742552197
- ISBN-10: 0742552195
- Artikelnr.: 23353745
- Herstellerkennzeichnung
- Libri GmbH
- Europaallee 1
- 36244 Bad Hersfeld
- gpsr@libri.de
- Verlag: Rowman & Littlefield Publishers
- Seitenzahl: 382
- Erscheinungstermin: 9. November 2007
- Englisch
- Abmessung: 229mm x 152mm x 22mm
- Gewicht: 619g
- ISBN-13: 9780742552197
- ISBN-10: 0742552195
- Artikelnr.: 23353745
- Herstellerkennzeichnung
- Libri GmbH
- Europaallee 1
- 36244 Bad Hersfeld
- gpsr@libri.de
Howard Brody is professor and director for the Institute for the Medical Humanities, University of Texas Medical Branch at Galveston. Prior to this appointment, Dr. Brody was University Distinguished Professor of family practice, and philosophy at Michigan State University, where he also sat on the faculty of the Center for Ethics and Humanities in the Life Sciences; he served as director of the Center from 1985-2000. Dr. Brody completed his residency in family practice at the University of Virginia Medical Center. He received his MD from the College of Human Medicine, Michigan State University, in 1976, and his PhD in Philosophy, also from Michigan State University, in 1977. He currently sits on the board of the American Society for Bioethics and the Humanities, and specializes in ethics and the doctor-patient relationship. He has authored five books, among them Stories of Sickness (2002) and The Placebo Response: How You Can Release the Body's Inner Pharmacy for Better Health (2000). For up-to-date news about the issues covered in Hooked, visit Dr. Brody's new blog.
Chapter 1 Introduction: The Tipping Point
Part 2 I. Overview
Chapter 3 1. The Good, the Bad, and the Ugly: A Story of Two Medications
Chapter 4 2. An Ethical Framework
Part 5 II. Specific Issues and Problems
Chapter 6 3. The Pharmaceutical Industry and the Free Market
Chapter 7 4. Patents, Generic Drugs, and Academic Science
Chapter 8 5. Research and Profits
Chapter 9 6. Suppression of Research Data
Chapter 10 7. The Quality of Pharmaceutical Research
Chapter 11 8. The Drug Rep: Historical Background
Chapter 12 9. The Drug Rep Today
Chapter 13 10. The Influence of Drug Reps: What the Data Show
Chapter 14 11. Continuing Medical Education
Chapter 15 12. Professional Organizations and Journal Advertising
Chapter 16 13. The Industry and the Consumer
Chapter 17 14. The FDA: From Patent Medicine to AIDS Drugs
Chapter 18 15. The FDA and the Industry, 1990-2004
Part 19 III. Toward Solutions
Chapter 20 16. Solutions: The Management and Divestment Strategies
Chapter 21 17. Solutions Requiring Enhanced Professionalism in Medicine
Chapter 22 18. Solutions Requiring Regulatory Reform
Chapter 23 Epilogue: Industry Woes and Professional Opportunities
Part 2 I. Overview
Chapter 3 1. The Good, the Bad, and the Ugly: A Story of Two Medications
Chapter 4 2. An Ethical Framework
Part 5 II. Specific Issues and Problems
Chapter 6 3. The Pharmaceutical Industry and the Free Market
Chapter 7 4. Patents, Generic Drugs, and Academic Science
Chapter 8 5. Research and Profits
Chapter 9 6. Suppression of Research Data
Chapter 10 7. The Quality of Pharmaceutical Research
Chapter 11 8. The Drug Rep: Historical Background
Chapter 12 9. The Drug Rep Today
Chapter 13 10. The Influence of Drug Reps: What the Data Show
Chapter 14 11. Continuing Medical Education
Chapter 15 12. Professional Organizations and Journal Advertising
Chapter 16 13. The Industry and the Consumer
Chapter 17 14. The FDA: From Patent Medicine to AIDS Drugs
Chapter 18 15. The FDA and the Industry, 1990-2004
Part 19 III. Toward Solutions
Chapter 20 16. Solutions: The Management and Divestment Strategies
Chapter 21 17. Solutions Requiring Enhanced Professionalism in Medicine
Chapter 22 18. Solutions Requiring Regulatory Reform
Chapter 23 Epilogue: Industry Woes and Professional Opportunities
Chapter 1 Introduction: The Tipping Point
Part 2 I. Overview
Chapter 3 1. The Good, the Bad, and the Ugly: A Story of Two Medications
Chapter 4 2. An Ethical Framework
Part 5 II. Specific Issues and Problems
Chapter 6 3. The Pharmaceutical Industry and the Free Market
Chapter 7 4. Patents, Generic Drugs, and Academic Science
Chapter 8 5. Research and Profits
Chapter 9 6. Suppression of Research Data
Chapter 10 7. The Quality of Pharmaceutical Research
Chapter 11 8. The Drug Rep: Historical Background
Chapter 12 9. The Drug Rep Today
Chapter 13 10. The Influence of Drug Reps: What the Data Show
Chapter 14 11. Continuing Medical Education
Chapter 15 12. Professional Organizations and Journal Advertising
Chapter 16 13. The Industry and the Consumer
Chapter 17 14. The FDA: From Patent Medicine to AIDS Drugs
Chapter 18 15. The FDA and the Industry, 1990-2004
Part 19 III. Toward Solutions
Chapter 20 16. Solutions: The Management and Divestment Strategies
Chapter 21 17. Solutions Requiring Enhanced Professionalism in Medicine
Chapter 22 18. Solutions Requiring Regulatory Reform
Chapter 23 Epilogue: Industry Woes and Professional Opportunities
Part 2 I. Overview
Chapter 3 1. The Good, the Bad, and the Ugly: A Story of Two Medications
Chapter 4 2. An Ethical Framework
Part 5 II. Specific Issues and Problems
Chapter 6 3. The Pharmaceutical Industry and the Free Market
Chapter 7 4. Patents, Generic Drugs, and Academic Science
Chapter 8 5. Research and Profits
Chapter 9 6. Suppression of Research Data
Chapter 10 7. The Quality of Pharmaceutical Research
Chapter 11 8. The Drug Rep: Historical Background
Chapter 12 9. The Drug Rep Today
Chapter 13 10. The Influence of Drug Reps: What the Data Show
Chapter 14 11. Continuing Medical Education
Chapter 15 12. Professional Organizations and Journal Advertising
Chapter 16 13. The Industry and the Consumer
Chapter 17 14. The FDA: From Patent Medicine to AIDS Drugs
Chapter 18 15. The FDA and the Industry, 1990-2004
Part 19 III. Toward Solutions
Chapter 20 16. Solutions: The Management and Divestment Strategies
Chapter 21 17. Solutions Requiring Enhanced Professionalism in Medicine
Chapter 22 18. Solutions Requiring Regulatory Reform
Chapter 23 Epilogue: Industry Woes and Professional Opportunities







